EU/3/03/146: Orphan designation for the treatment of renal-cell carcinoma


Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2006 on request of the sponsor.

On 30 June 2003, orphan designation (EU/3/03/146) was granted by the European Commission to Chiron B. V., the Netherlands, for aldesleukin (inhalation use) for the treatment of renal cell carcinoma.

The sponsorship was transferred to Chiron Corporation Limited, United Kingdom, in November 2005.

Key facts

Active substance
Intended use
Treatment of renal-cell carcinoma
Orphan designation status
EU designation number
Date of designation
Chiron Corporation Limited
Symphony House
7 Cowley Business Park, High Street
Cowley, Uxbridge
United Kingdom
Telephone: +44 20 85 80 40 00
Telefax: +44 20 85 80 40 97

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating
1 rating